Evommune (EVMN) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ARS Pharmaceuticals (SPRY) has outperformed Evommune (EVMN) over the past year, losing 61.0% versus a loss of 62.4%. ARS Pharmaceuticals is the larger company by market cap ($297.6 million vs $291.1 million), about 1.0 times the size, while Evommune is growing revenue faster (+85.7% vs -5.5%). ARS Pharmaceuticals converts more of its revenue into profit, with a net margin of -203.3% versus -529.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | SPRY |
|---|---|---|
| Share price | $7.04 | $2.96 |
| Market cap | $291.10M | $297.56M |
| 1-day change | -2.76% | -11.90% |
| YTD return | -58.88% | -74.59% |
| 1-year return | -62.37% | -61.00% |
| 5-year return | — | -58.83% |
| EPS (TTM) | $-3.83 | $-2.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.00M | $84.28M |
| Revenue growth (YoY) | +85.71% | -5.46% |
| Net income (latest FY) | $-68.87M | $-171.30M |
| Operating margin | -623.62% | -212.92% |
| Net margin | -529.77% | -203.25% |
| 52-week high | $33.20 | $13.15 |
| 52-week low | $4.94 | $2.44 |
| Distance from 52-week high | -78.80% | -77.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +210.94% | +474.32% |
| Average volume | 841.65K | 1.83M |
| Shares outstanding | 41.35M | 100.53M |
| Employees | 48 | 203 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARS Pharmaceuticals is more profitable, keeping -203.3 cents of every revenue dollar as net income versus -529.8 cents for Evommune.
- Evommune grew revenue faster in its latest fiscal year (+85.71% vs -5.46%).
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees
EVMN vs SPRY FAQ
Which is bigger, Evommune or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $297.56M compared with $291.10M for Evommune (EVMN).
Which stock has performed better over the past year, EVMN or SPRY?
SPRY returned -61.00% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.
Are Evommune and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.